Loading
OCD / Depression / MagVenture MagPro System with Brainsight neuronavigation device · Interventional Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered clinical trial protocol, not a completed study. No efficacy or safety results are reported in this registry record. The trial aims to test whether accelerated 5-day rTMS targeting either LPFC or DMPFC improves depression and OCD symptoms more rapidly than standard protocols, with secondary fMRI biomarker analysis.
Interventional, Randomized, Crossover, Open label, Treatment purpose. Depression, OCD; age from 18 Years; to 75 Years. Intervention: Depression - DMPFC target to (for non-responders) LPFC targ…; OCD - DMPFC target to (for non-responders) LPFC target. Compared with: Depression - LPFC target to (for non-responders) DMPFC targ… — Active Comparator; OCD - LPFC target to (for non-responders) DMPFC target — Active Comparator. n = 500. 1 site: United States.
This is a registered clinical trial protocol, not a completed study. No efficacy or safety results are reported in this registry record. The trial aims to test whether accelerated 5-day rTMS targeting either LPFC or DMPFC improves depression and OCD symptoms more rapidly than standard protocols, with secondary fMRI biomarker analysis.
This is a registry record only; no results, efficacy, safety data, or outcome comparisons are reported. Primary hypothesis and protocol design are stated, but no interim or final efficacy or harm data are available.
No clinical impact can be assessed from this registry record, as results are not yet reported. Clinicians should monitor for publication of outcomes once the trial completes.
This is a clinical trial registry record with no reported results; it describes a planned interventional study testing an accelerated rTMS protocol in depression and OCD.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record, as results are not yet reported. Clinicians should monitor for publication of outcomes once the trial completes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04982757). This is a study registration, not published results. Lead sponsor: Weill Medical College of Cornell University. Recruitment status: ENROLLING_BY_INVITATION. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 500 participants (ESTIMATED). Conditions: Depression, OCD. Interventions: DEVICE: MagVenture MagPro System with Brainsight neuronavigation device. Primary outcome measures: Percent Change in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores for participants with OCD , Baseline to Treatment End: Day 5, 10, 15, or 20 (depending on number of 5-day treatment courses administered); Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores for participants with treatment resistant depression , Baseline to Treatment End: Day 5 or 10 (depending on number of 5-day treatment courses administered). Brief summary: Repetitive transcranial magnetic stimulation (rTMS) is a FDA-approved treatment for depression and Obsessive Compulsive Disorder (OCD). The goal of the study is to learn how to optimize the treatment to improve symptoms of depression and OCD. This research project will test a new accelerated 5-day accelerated rTMS protocol for treating symptoms of depression and OCD. A second goal of this study is to identify biomarkers of depression and OCD in the brain using functional magnetic resonance imaging (fMRI). This approach will predict who will benefit from TMS, determine the optimal treatment target, and improve treatment outcomes. Subjects will receive a clinical assessment of symptoms and an fMRI brain scan before and after each treatment course to measure the effect of treatment on symptom severity and on fMRI measures of functional connectivity. Participants will be randomized to receive rTMS targeting either the lateral prefrontal cortex (LPFC) or the dorsomedial prefrontal cortex (DMPFC). Participants will complete a 5-day course of rTMS delivered hourly for 10 hours per day. Participants who show a partial response to treatment but not a full response will then receive a second 5-day course. Treatment non-responders will be crossed over to receive rTMS targeting the opposite brain area. The primary hypothesis is that accelerated rTMS treatment will yield rapid improvement in symptoms for patients with depression and OCD in just 5 days, and that response rates can be further improved by adding a second 5-day treatment course.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.